An Integrated Analysis of Dostarlimab Immunogenicity

Monoclonal antibodies that block the interaction between programmed cell death 1 (PD-1) and its ligand (PD-L1) have revolutionized cancer immunotherapy. However, immunogenic responses to these new therapies—such as the development of antidrug antibodies (ADAs) and neutralizing antibodies (NAbs)—may...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Sharon, Bowsher, Ronald R., Clancy, Amanda, Rosen, Amy, Zhang, Mingxuan, Yang, Ying, Koeck, Kathleen, Gao, Minggeng, Potocka, Elizabeth, Guo, Wei, Jen, Kai Yu, Im, Ellie, Milton, Ashley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321970/
https://www.ncbi.nlm.nih.gov/pubmed/34324079
http://dx.doi.org/10.1208/s12248-021-00624-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321970/
https://www.ncbi.nlm.nih.gov/pubmed/34324079
http://dx.doi.org/10.1208/s12248-021-00624-7

Ejemplares similares